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GUEST EDITORIALS 

ERADICATION OF GASTRIC HELICOBACTER PYLORI: 

ARE WE GETTING THERE? 

E. Pullicino 
In 1984 Marshall and Warren discovered and 
isolated a curved bacillus living in the stomach of 
patients with gastritis and peptic ulceration I. 
Subsequent workers2 demonstrated that they 
could induce persistent gastritis by ingesting the 
bacillus which had been up till then regarded as a 
commensal living in areas of gastric mucosal 
damage. Over the following decade, this 
organism named as Helicobacter Pylori (HP), has 
been shown to play a major role in the causation 
of duodenal ulcers. Benign ulcers appearing in 
stomachs which have not been exposed to non­
steroidal anti-inflammatory drugs have also been 
strongly associated with gastric HP colonisation. 
HP has also been implicated in the aetiology of 
non-ulcer dyspepsia, gastric carcinoma and 
primary gastric lymphoma. 
Amongst these diseases, the most challenging 
problem in the last decade has been that of 
duodenal ulcer recurrence after initial healing by 
modern H2 Blocker drugs such as Ranitidine. 
This phenomenon is now largely attributed to 
coexisting colonisation of the stomach by H p3. 
The incidence of duodenal ulcer recurrence can 
be dramatically reduced if co-existing HP is 
successfully eradicated4. The recent consensus 
that HP-associated duodenal ulcer should be 
treated by HP eradication will probably be 
extended to HP-associated gastric ulcer in the 
near future. However, the potential benefit of 
eradication of HP in populations at high risk of 
gastric cancer has not yet been properly 
addressed. 
This spiral-shaped gram-negative rod has carved 
out for itself a unique ecological niche in or near 
the un stirred mucous layer lining the gastric 
surface and pits. This remarkable evolution has 
been achieved by acquiring the capacity to buffer 
lethal gastric acid with ammonia (produced in the 
bacillus by the action of urease on urea)5. 
Although the ecology of the organism has not yet 
been studied in detail, many publications have 
much greater acid-producing aCtIVIty in the 
gastric body suggests that mechanisms protecting 
HP against attack by gastric acid are not yet 
completely evolved. 
Colonisation of the gastric antrum stimulates the 
antral "G" cells to release an enterohormone 
called gastrin which in turn leads to excess 
production of acid by the gastric parietal cells. 
This hyperchlorhydria is believed to be one of 
the mechanisms by which H P produces duodenal 
ulceration. Hyperchlorhydria causes m:eas of 
gastric metaplasia7 to appear in the duodenum 
which are soon colonised by more HP organisms. 
This VICIOUS circle can be broken by 
administering antimicrobials selected on the basis 
of invitro sensitivities of the organism and on 
their ability to heal HP-associated gastritis. 
Because of the ease with which resistant strains 
of HP emerge, triple therapy (bismuth subcitrate, 
amoxycillin and metronidazole) continues to be 
the most popular regimen. Endoscopic studies of 
DU patients using multiple gastric biopsies have 
shown that DU healing and short term 
eradication can be achieved in over 85% of 
patients8. In such patients, the incidence of 
recurrence of HP in repeat gastric biopsies one 
year later is typically 50% 9,10. Duodenal ulcer 
recurrences are confined almost exclusively to 
those patients in whom HP persists in the gastric 
mucosal I. 
Persistence of HP, with its attendant risks of 
chronic duodenal ulcer, has been partly attributed 
to reinfection of the stomach. This is possible 
especially where sanitary conditions are poorl2 , 
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m overcrowded areas!3, in paediatric 
institutions 14, and in endoscopy units if 
equipment is not adequately decontaminated. 
However, most failures of eradication of HP 
infections are thought to be due to incomplete 
antimicrobial action. This may result from poor 
drug compliance or from primary drug resistance. 
The large number of tablets prescribed in the 
triple therapy regimen increases the frequency of 
side effects and reduces compliance. Primary 
resistance to one or more of the antibiotics may 
precede the treatment especially in females who 
were prescribed metronidazole previously for 
pelvic inflammatory disease. The efficacy of 
these antibiotics is likely to be limited by the fact 
that key metabolic pathways in the bacterium that 
could be targeted by antimicrobials have not yet 
been elucidated in detail. In addition to its habitat 
in the gastric mucous, HP has been found inside 
gastric mucosal cells15 . This could further 
decrease its susceptibil'ty to antibiotics. 
Recent developments in the field of duodenal 
ulcer therapy have raised the· hopes that this 
therapeutic hurdle can now be overcome by an 
alternative approach. There have been several 
recent trials l6 • 17 in which a single antimicrobial 
(amoxycillin up to 3 grams daily) was combined 
with a potent gastric acid suppressor 
(Omeprazole up to 60 mg daily). These regimens 
achieved eradication rates of 80 to 90% which 
are similar to those obtained using triple 
antibiotic therapy. It is logical to postulate that an 
organism which has specialised and evolved in 
such a way as to flourish in acid conditions will 
fare badly when these conditions are suddenly 
removed by potent acid suppression. Indeed the 
addition of Omeprazole drastically reduces the 
minimum inhibitory concentration of amoxycillin 
on HP in vivo. It has been suggested that when 
acid is suddenly abolished much of the ammonia 
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